Catalent (NYSE:CTLT) said today that it inked a $139 million deal to acquire Juniper Pharmaceuticals (NSDQ:JNPR) and its early-stage product development services.
The company noted that its Juniper acquisition, set at $11.50 per share, will complement Catalent’s formulation development offerings, bioavailability solutions and clinical-scale oral dose manufacturing capabilities.
Get the full story at our sister site, Drug Delivery Business News.
The post Catalent expands early-phase development skills with $139m Juniper buyout appeared first on MassDevice.